Alimera Sciences, Inc. (ALIM) |
3.9 0.03 (0.78%) 03-27 16:00 |
Open: | 3.88 |
High: | 3.945 |
Low: | 3.78 |
Volume: | 41,822 |
Market Cap: | 204(M) |
PE Ratio: | -4.64 |
Exchange: | NASDAQ Global Market |
Industry: | Drug Manufacturers - Specialty & Generic |
Sector: | Healthcare |
Technical analysis | ||||
sell | buy |
Resistance 2: | 4.99 |
Resistance 1: | 4.27 |
Pivot price: | 3.95 |
Support 1: | 3.64 |
Support 2: | 3.25 |
52w High: | 4.38 |
52w Low: | 1.56 |
Alimera Sciences, Inc., a pharmaceutical company, engages in the development and commercialization of ophthalmic pharmaceuticals in the United States and internationally. It offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye. The company sells its products to physician offices, pharmacies, and hospitals through direct sales and distributors. It has a collaboration agreement with EyePoint Pharmaceuticals US, Inc. for the development and sale of insert technology to deliver other corticosteroids to the back of the eye for the treatment and prevention of eye diseases in humans or to treat diabetic macular edema. The company was incorporated in 2003 and is headquartered in Alpharetta, Georgia.
EPS | -0.840 |
Book Value | 0.880 |
PEG Ratio | 0.00 |
Gross Profit | 0.000 |
Profit Margin (%) | -24.93 |
Operating Margin (%) | 2.75 |
Return on Assets (ttm) | -1.2 |
Return on Equity (ttm) | -158.8 |
Tue, 26 Mar 2024
Alimera Sciences (NASDAQ:ALIM) Now Covered by Analysts at Maxim Group - Defense World
Sun, 24 Mar 2024
With 47% ownership, Alimera Sciences, Inc. (NASDAQ:ALIM) has piqued the interest of hedge funds investors - Yahoo Canada Shine On
Thu, 21 Mar 2024
Alimera Sciences (NASDAQ:ALIM) Stock Price Crosses Above Two Hundred Day Moving Average of $3.53 - Defense World
Thu, 21 Mar 2024
Alimera Sciences (NASDAQ:ALIM) Stock Price Passes Above 200-Day Moving Average of $3.53 - MarketBeat
Thu, 07 Mar 2024
Alimera Sciences, Inc. (ALIM) Q4 2023 Earnings Call Transcript - Seeking Alpha
Thu, 07 Mar 2024
Alimera Sciences: Q4 Earnings Snapshot - Opelika Auburn News
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |